In December 2022, the US company halted dosing in one of the groups taking part in a Phase I/II study its cancer candidate MGTA-117, which is Magenta’s most advanced targeted conditioning product candidate designed to deplete target cells prior to a patient undergoing stem cell transplant or receiving an ex vivo gene therapy product.